Lang Wu, PhD

Lang Wu, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 564-5965

Full Member, Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawaiʻi Cancer Center

Academic Appointment(s):
Assistant Professor, Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa

PhD, Clinical and Translational Science, Mayo Clinic College of Medicine
Postdoctoral Fellow, Cancer and Molecular Epidemiology, Vanderbilt University Medical Center

Research Focus

Dr. Wu’s research involves the epidemiologic investigation of genetic, molecular, nutritional, and lifestyle factors in cancer etiology and prognosis. His long-term research goal is to translate the gained knowledge for prevention, risk assessment, early detection, and prognosis prediction of human malignancies, especially for prostate and pancreatic cancer. He has been supported by a NCI K99/R00 Pathway to Independence Award to study roles of polyunsaturated fatty acids in pancreatic cancer etiology.

Currently, a main focus of Dr. Wu’s research is to conduct integrative multi-omics (genomics, transcriptomics, methylomics, proteomics, metabolomics, etc.) studies to identify novel cancer susceptibility genes and biomarkers. He has led several large transcriptome-wide association studies evaluating associations of genetically-predicted gene expression levels with risks of breast, prostate, and pancreatic cancers, which identified multiple novel susceptibility gene candidates for these cancers. He is also investigating DNA methylation, protein, and metabolite biomarkers associated with human cancers using genetic instruments.  Furthermore, Dr. Wu is studying disease risk prediction using genetic, molecular, and other information.

Selected Publications

Wu C, Zhu J, King A, Tong X, Lu Q, Park JY, Wang L, Gao G, Deng HW, Yang Y, Knudsen KE, Rebbeck TR, Long J, Zheng W, Pan W, Conti DV, Haiman CA, Wu L. (2021). Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. Cancer Commun (Lond);Sep 14. Online ahead of print. PMID: 34520132.

Liu D, Zhou D, Sun Y, Zhu J, Ghoneim D, Wu C, Yao Q, Gamazon ER, Cox NJ, Wu L. (2020). A Transcriptome-Wide Association Study Identifies Candidate Susceptibility Genes for Pancreatic Cancer Risk. Cancer Res. PMID: 32907841.

Wu L, Yang Y, Guo X, Shu XO, Cai Q, Shu X et al. (2020). An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nat Comm. PMID: 32764609 PMCID: PMC7413371.

Wu L, Shu X, Bao J, Guo X, the PRACTICAL, CRUK, BPC3, CAPS, PEGASUS consortia, Kote-Jarai Z, Haiman CA, Eeles RA, Zheng W. (2019). Analysis of over 140,000 European descendants identifies genetically-predicted blood protein biomarkers associated with prostate cancer risk. Cancer Res;Sep;79(18):4592-4598. PMID: 31337649. PMCID: PMC6744971.

Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, et al. (2018). A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet;Jul;50(7):968-978. PMID: 29915430. PMCID: PMC6314198.

Publication list via PubMed

Active Grants

L. Wu, PI
National Cancer Institute
R00 CA218892
"Uncovering roles of polyunsaturated fatty acids in pancreatic cancer etiology"